Xin Lang Cai Jing·2025-11-13 11:29Core Viewpoint - Pfizer is seeking to sell its remaining stake in COVID-19 vaccine partner BioNTech, marking the end of a highly profitable collaboration during the pandemic [1] Group 1: Pfizer's Actions - Pfizer plans to sell approximately 4.55 million American Depositary Receipts (ADRs) at a price range of $108 to $111.70 per share, potentially generating about $508 million if priced at the upper limit [1] - The company recently acquired obesity startup Metsera Inc. for $10 billion, aiming to replace declining COVID-19 business revenues with a new weight-loss drug [1] Group 2: BioNTech's Transition - BioNTech is returning to its original focus on cancer treatment research, utilizing accumulated funds to support its studies [1] - The company has entered into a collaboration agreement with Bristol Myers Squibb valued at up to $11.1 billion [1]